Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.

[1]  Y. Ngo,et al.  Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. , 2012, Journal of hepatology.

[2]  A. Burroughs,et al.  Non-invasive assessment of liver fibrosis , 2012, Annals of gastroenterology.

[3]  Y. Ngo,et al.  Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  Julien Vergniol,et al.  Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard. , 2012, Journal of hepatology.

[5]  V. de Lédinghen,et al.  Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive , 2012, Hepatology.

[6]  V. de Lédinghen,et al.  FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate. , 2011, Clinics and research in hepatology and gastroenterology.

[7]  T. Poynard,et al.  The Risk of Multiplying Diagnostic Combinations in the Absence of a Perfect Gold Standard For a Fibrosis Test , 2011, The American Journal of Gastroenterology.

[8]  Y. Ngo,et al.  Prognostic value of liver fibrosis biomarkers: a meta-analysis. , 2011, Gastroenterology & hepatology.

[9]  Julien Vergniol,et al.  Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. , 2011, Gastroenterology.

[10]  J. Talwalkar,et al.  Noninvasive assessment of liver fibrosis , 2011, Hepatology.

[11]  Y. Ngo,et al.  Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age , 2011, BMC gastroenterology.

[12]  T. Poynard.  First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy. , 2011, Journal of hepatology.

[13]  P. Crotty,et al.  Prevalence, risk factors and causes of discordance in fibrosis staging by transient elastography and liver biopsy , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[14]  Laurent Castera,et al.  Non-invasive assessment of liver fibrosis: are we ready? , 2010, The Lancet.

[15]  V. de Lédinghen,et al.  Pitfalls of liver stiffness measurement: A 5‐year prospective study of 13,369 examinations , 2010, Hepatology.

[16]  V. de Lédinghen,et al.  The combination of a blood test and Fibroscan improves the non‐invasive diagnosis of liver fibrosis , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[17]  Mihai Voiculescu,et al.  SAFE biopsy: A validated method for large‐scale staging of liver fibrosis in chronic hepatitis C , 2009, Hepatology.

[18]  Gérard Forzy,et al.  Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C , 2009, Hepatology.

[19]  D. Thabut,et al.  Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis Markers , 2008, PloS one.

[20]  F. Carrat,et al.  How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. , 2008, Clinical chemistry.

[21]  Eva Herrmann,et al.  Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. , 2008, Gastroenterology.

[22]  P. Bossuyt,et al.  Evaluation of diagnostic tests when there is no gold standard. A review of methods. , 2007, Health technology assessment.

[23]  P Tappenden,et al.  Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. , 2007, Health technology assessment.

[24]  Paul Calès,et al.  Sources of variability in histological scoring of chronic viral hepatitis , 2005, Hepatology.

[25]  V. de Lédinghen,et al.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.

[26]  V. Paradis,et al.  Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.

[27]  Xiao-Hua Zhou,et al.  Statistical Methods in Diagnostic Medicine , 2002 .

[28]  A. Hadgu,et al.  A biomedical application of latent class models with random effects , 2002 .

[29]  M. Tan,et al.  Random effects models in latent class analysis for evaluating accuracy of diagnostic tests. , 1996, Biometrics.

[30]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.

[31]  V. de Lédinghen,et al.  Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. , 2012, Journal of hepatology.

[32]  S. Bertrais,et al.  A New Combination of Blood Test and Fibroscan for Accurate Non-Invasive Diagnosis of Liver Fibrosis Stages in Chronic Hepatitis C , 2011, The American Journal of Gastroenterology.

[33]  Bryan Lau,et al.  Exceeding the limits of liver histology markers. , 2009, Journal of hepatology.

[34]  Y. Ngo,et al.  Open Access Research Article Prevalence of Liver Fibrosis and Risk Factors in a General Population Using Non-invasive Biomarkers (fibrotest) , 2022 .